Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.23.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 67,772 $ 61,880 $ 42,722
Collaboration and License Agreements and Supply Agreements      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 67,772 61,880 42,722
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 9,752 11,483 11,407
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 11,600 42,780 26,075
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,695 4,576 5,042
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 10,897    
Collaboration and License Agreements and Supply Agreements | Vaxcyte      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 3,828 3,041 198
Collaboration and License Agreements and Supply Agreements | BioNova Pharmaceuticals, Ltd. ("BioNova")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 4,000    
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 25,000    
BMS Agreement and the 2018 BMS Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 9,752 11,483 11,407
BMS Agreement and the 2018 BMS Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues     2,974
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 700 940 646
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 9,052 10,543 7,787
2020 Merck Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 11,600 42,780 26,075
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 862 35,098 18,474
2020 Merck Master Services Agreement | Contingent Payment Earned      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 10,000    
2020 Merck Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 577 2,666 5,485
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   610 1,852
2020 Merck Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 161 4,406 264
2019 EMD Serono Supply Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,695 4,576 5,042
2019 EMD Serono Supply Agreement | Contingent Payment Earned      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue   2,000 1,000
2019 EMD Serono Supply Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 510 851 1,316
2019 EMD Serono Supply Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,185 1,725 2,726
Supply Agreement | Vaxcyte      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 3,828 3,041 198
Supply Agreement | Vaxcyte | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,356 1,131 184
Supply Agreement | Vaxcyte | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,472 $ 1,910 $ 14
Astellas License and Collaboration Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 10,897    
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 3,940    
Astellas License and Collaboration Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,878    
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 5,079